Sort
51,593 grants matching “hepatitis”
Thrombocytopoiesis in Diabetes: Role of Damage Associated Molecular Patterns
$496,290Prabhakara Reddy Nagareddy · University Of Alabama At Birmingham · R01 · FY2019 · HL
Functional Dynamics of Cytochrome P4503A4
$496,257William M Atkins · University Of Washington · R01 · FY2018 · GM
Mechanism of Proteotoxicity and Experimental Therapeutic Approaches in Porphyria
$496,238M Bishr Omary · Rutgers Biomedical And Health Sciences · R01 · FY2023 · DK
Mechanism of Proteotoxicity and Experimental Therapeutic Approaches in Porphyria
$496,238M Bishr Omary · Rbhs-Robert Wood Johnson Medical School · R01 · FY2022 · DK
Hepatic CYP enzymes and host-pathogen interactions
$496,223Edward T Morgan · Emory University · R01 · FY2010 · DK
Delineating the molecular mechanisms of hepatocyte-to-cholangiocyte reprogramming
$496,215Donghun Shin · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · DK
Role of protein mediate fatty acid uptake in liver cancer
$496,197Andreas Stahl · University Of California Berkeley · R01 · FY2022 · CA
IN 2018, OUR TEAM IDENTIFIED A NOVEL EQUINE PARVOVIRUS, NAMED EQUINE PARVOVIRUS HEPATITIS (EQPV-H). THIS VIRUS IS STRONGLY ASSOCIATED WITH THEILER'S DISEASE, A HIGHLY FATAL SYNDROME OF FULMINANT HEPATITIS IN HORSES. THIS PROJECT WILL WORK ON FURTHER IMPROVING OUR UNDERSTANDING OF THE EPIDEMIOLOGY AND PATHOGENIC MECHANISMS OF THIS NOVEL EQUINE PARVOVIRUS. THE SPECIFIC SCIENCE OBJECTIVES ARE TO PERFORM EPIDEMIOLOGIC MODELING OF NATURAL EQPV-H INFECTION KINETICS AND TRANSMISSION IN HORSES; TO CHARACTERIZE THE LIVER PATHOGENICITY OF EQPV-H TO FURTHER ESTABLISH ITS CLINICAL SIGNIFICANCE AND IMPROVE DIAGNOSTIC MEASURES; AND TO DETERMINE THE IMMUNOPATHOGENESIS OF EQPV-H. THE COMBINATION OF THIS PROPOSED WORK PROPOSED WILL LEAD TO A BETTER UNDERSTANDING OF THE EPIDEMIOLOGY AND PATHOGENICITY OF EQPV-H, WHICH IS ESSENTIAL TO IMPROVE (I) DIAGNOSTICS OF EQUINE LIVER DISEASE AND (II) MANAGEMENT STRATEGIES, INCLUDING FUTURE VACCINE DEVELOPMENT AND THERAPEUTIC INTERVENTION, ALL GEARED TOWARDS CONTROL AND PREVENTION OF DISEASE CAUSED BY EQPV-H IN THE EQUINE POPULATION.
$496,190Cornell University · · FY2020 · National Institute of Food and Agriculture
Role of protein mediate fatty acid uptake in liver cancer
$496,153Andreas Stahl · University Of California Berkeley · R01 · FY2019 · CA
MIRA-Regulation of drug metabolizing enzymes
$496,125Todd C. Skaar · Indiana University Indianapolis · R35 · FY2023 · GM
MIRA-Regulation of drug metabolizing enzymes
$496,125Todd C. Skaar · Indiana University Indianapolis · R35 · FY2022 · GM
MIRA-Regulation of drug metabolizing enzymes
$496,125Todd C. Skaar · Indiana University Indianapolis · R35 · FY2019 · GM
MIRA-Regulation of drug metabolizing enzymes
$496,125Todd C. Skaar · Indiana University Indianapolis · R35 · FY2020 · GM
TNF Alpha and Recovery from Alcoholic Liver Injury
$496,125Anna Mae Elizabeth Diehl · Duke University · R01 · FY2023 · AA
MIRA-Regulation of drug metabolizing enzymes
$496,125Todd C. Skaar · Indiana University Indianapolis · R35 · FY2021 · GM
Metabolism of islets of langerhans and hormone release
$496,114Franz M Matschinsky · University Of Pennsylvania · R01 · FY2010 · DK
DECONSTRUCTING INFLAMMATION AND ALTERED MICROBIOTA IN METABOLIC SYNDROME
$496,103Andrew T Gewirtz · Georgia State University · R01 · FY2023 · DK
Advancing our Understanding of Rare Pediatric Liver Diseases
$496,094Barbara Anne Haber · Children'S Hosp Of Philadelphia · U01 · FY2009 · DK
Cardiovascular Inflammation Reduction Trial (CIRT): DCC
$496,073Robert J Glynn · Brigham And Women'S Hospital · U01 · FY2011 · HL
(PQ8) Predicting immune-related toxicity in the adjuvant melanoma setting with checkpoint inhibition
$495,996Iman Osman · New York University School Of Medicine · R01 · FY2021 · CA
Development of a topical malaria vaccine.
$495,962Elizabeth H Nardin · New York University School Of Medicine · R01 · FY2014 · AI
Development of a topical malaria vaccine.
$495,942Elizabeth H Nardin · New York University School Of Medicine · R01 · FY2015 · AI
MicroRNA-Based Therapeutics for Rare Cystic Kidney Diseases
$495,923Peter Igarashi · Ut Southwestern Medical Center · RC1 · FY2009 · DK
Photoperiodic Control of Obesity
$495,895Timothy Jon Bartness · Georgia State University · R37 · FY2014 · DK
Human Liver Tissue & Hepatocytes Research Resource (HLTHRR)
$495,889David A Geller · University Of Pittsburgh At Pittsburgh · R24 · FY2024 · DK